Bentley Pharmaceuticals Announces the Signing of a Supply Agreement for the Supply of Insulin for Its Intranasal Delivery System.Business/Medical Editors NORTH HAMPTON North Hampton is the name of several places in the United States:
Bentley Pharmaceuticals, Inc. (AMEX AMEX See: American Stock Exchange : BNT BNT Bentley Pharmaceuticals, Inc. (stock symbol) BNT Boston Naming Test (psychology) BNT Bermuda National Trust BNT Bulgarian National TV BNT Broadband Network Termination BNT Binary File Transfer ), a drug delivery company with a commercial presence in Europe, announced today the signing of a supply agreement with a large European company for the clinical and commercial supply of recombinant human insulin Noun 1. recombinant human insulin - a form of insulin (trade name Humulin) made from recombinant DNA that is identical to human insulin; used to treat diabetics who are allergic to preparations made from beef or pork insulin Humulin . Specific terms of the agreement and the identity of the supplier were not disclosed. James R. Murphy, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , commented, "We are very pleased to obtain a source of high quality insulin for our clinical evaluations and future commercial needs. For years, the Years, The the seven decades of Eleanor Pargiter’s life. [Br. Lit.: Benét, 1109] See : Time supply of insulin has been very limited and expensive, restricting the advancement of innovative delivery products. Our pre-clinical evaluation of intranasal in·tra·na·sal adj. Within the nose. insulin formulations has been encouraging because our formulations have exceeded the bio-availability levels of other alternative delivery forms currently being developed. Pre-clinical toxicological evaluation of these formulations has shown the absence of any gross or microscopic signs of irritation or abnormalities. We will be evaluating the delivery of insulin from a small, discreet and metered nasal spray that can be carried in a patient's pocket." Murphy continued, "Diabetes is a leading metabolic disorder currently affecting approximately 100 million people worldwide that is expected to affect more than 300 million people within the next 25 years. The market size in the United States alone exceeds $3 billion annually and some estimate the worldwide market to exceed $10 billion. Diabetic patients who must endure frequent syringe injections are eagerly awaiting less invasive methods of administering their medications. Alternative methods of delivery not only improve their quality of life but contribute to maintaining patients' daily regimen of compliance." Bentley Pharmaceuticals, Inc. is a drug delivery company focused upon improving the absorption of a wide range of drugs and peptides through proprietary drug delivery technologies, which it intends to commercialize in the U.S. and other major markets by licensing to other pharmaceutical companies. Bentley also manufactures and commercializes branded and generic products in Europe for the treatment of cardiovascular, gastrointestinal, neurological and infectious diseases through its subsidiaries, Laboratorios Belmac and Laboratorios Davur. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, the ability to find effective market distribution channels, development of new products, regulatory approval processes, the impact of competitive products or pricing, unpredictability of patent protection, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. Copies of the Company's press releases and other information may be obtained through Bentley's web site at www.bentleypharm.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion